Practical Strategies for Multidisciplinary Recognition and Management of Adverse Events Associated with Bispecific Antibodies
Tracking # 20-1314919
Free
Course overview
Pharmacists play a vital and evolving role in hematology/oncology care, with growing evidence showing that pharmacist involvement in patient care improves personalized care and monitoring and managing adverse events; however, ensuring these outcomes are realized requires appropriate training and education so that clinical pharmacists, employed in a variety of settings, can perform integrated care functions. This is especially true for patients with relapsed/refractory (R/R) multiple myeloma (MM) who are treated with bispecific antibodies. These drugs with differing mechanisms of action, have a unique set of toxicities that require nuanced monitoring and management. This learning hub provides pharmacists with the education and resources needed to effectively translate the latest evidence into multidisciplinary clinical practice and improve patient outcomes.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Pharmacist
Disclosure statements
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:
Beth Faiman PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO
Consultant: Amgen, Bristol Myers Squibb, Janssen, Karyopharm, Pfizer, Sanofi
Rebecca LaRue, PharmD, BCOP
No financial relationships to disclose
Hans Lee, MD
Consultant: AbbVie, Alexion Pharmaceuticals, Allogene Therapeutics, Bristol Myers Squibb, GlaxoSmithKline, Janssen, Menarini Silicon Biosystems, Pfizer, Regeneron, Takeda
Grants/Research Support: Bristol Myers Squibb, GlaxoSmithKline, Janssen, Regeneron, Takeda